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Catherine A Hankins1, Mark A Wainberg2* and Robin A Weiss3We commemorate the sad loss of a true leader in retro-
viral disease, Professor Joep Lange, former President of
the International AIDS Society. Our friend and col-
league Joep perished on July 17, 2014 together with his
beloved partner Jacqueline van Tongeren, while flying
from Amsterdam to the International AIDS Conference
in Melbourne aboard Malaysian Airlines flight 17. Joep
contributed in compelling fashion to much of the pro-
gress accomplished thus far in combatting the HIV epi-
demic. He lost his life together with Jacqueline and four
other individuals on their way to the conference, shot
down by killers whose own families and friends might
have benefited in the past and may benefit in the future
from Joep’s many contributions to our field.
Joep was pivotally involved from the earliest days of anti-
retroviral therapy, helping devise the important strategies
for combatting HIV infection that continue to be employed
today. Together with Jaap Goudsmit, Frank Miedema, and
Roel Coutinho, he played a key role in establishing the
multidisciplinary group of investigators in Amsterdam that
pioneered much of our understanding today of HIV and its
disease course. They established well-characterised cohorts
of HIV-positive people and those at higher risk of HIV ex-
posure, sought to understand transmission dynamics, and
helped elucidate HIV pathogenesis, progression to AIDS,
and the benefits of early treatment. From the mid-1980s
onwards, the Dutch group made immense contributions to
the field and it did not take long for Joep to begin to trans-
late the insights gained in Amsterdam into strategies to
ameliorate the burden of AIDS in Africa.
He began his career at the University of Amsterdam, re-
ceiving his MD in 1981 and PhD in 1987. From 1992 to
1995, he was Chief of Clinical Research and Drug Devel-
opment at the Global Programme on AIDS at the World
Health Organization in Geneva. Joep played a key role at
WHO during the time that the spread of HIV was pro-
ceeding virtually unabated and when very few antiretro-
viral drugs were available. He advocated passionately for* Correspondence: mark.wainberg@mcgill.ca
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clinical trials that embraced the simultaneous use of three
drugs to combat viral replication. Indeed, he was among
the first to understand that such a strategy was mandated
by the ability of HIV to mutate rapidly, both in the ab-
sence and presence of drug pressure. Throughout his car-
eer, Joep maintained a keen interest in questions relating
to viral pathogenesis and conducted early work on this
topic. His PhD thesis at the University of Amsterdam was
entitled “Serological markers in HIV infection” and Joep
was among the first to demonstrate that high levels of
viral p24 protein in the circulation were a key prognostic
indicator of disease progression.
Joep was a strong advocate for people living with HIV
throughout the world, arguing repeatedly that they should
have access to excellent antiretroviral drugs regardless of
where they lived. When confronted with potential prob-
lems relating to drug access, he retorted: “If we can get
cold Coca-Cola and beer to every remote corner of Africa,
it should not be impossible to do the same with drugs”.
In recent years, Joep took a strong interest in the pos-
sibility of achieving HIV eradication from the body i.e. a
cure for HIV infection. He keenly immersed himself in
arguments as to the feasibility of approaches that might
lead to an end to HIV transmission and his sharp mind
was second to none in regard to how best to use all of
our available tools toward this goal. Indeed, Joep was
one of the first scientists to publish on the topic of cellu-
lar reservoirs of HIV and on HIV persistence. He was
also among the first to understand that antiretroviral
drugs might be used not only to treat individuals with
HIV but also as agents to protect people from acquiring
HIV infection, concepts that have now become firmly
established within the field. He felt so strongly about
HIV pre-exposure prophylaxis that he was dismayed
when early trials encountered controversy. Joep was dir-
ectly involved in studies on the prevention of HIV trans-
mission from mothers with HIV infection to their
offspring through the use of antiretroviral agents.
Joep played a key role in many international studies,
beginning with efforts to deal with the HIV epidemic in
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providing affordable HIV care in Africa. Joep lectured
throughout the world and participated on a regular basis
in mentorship activities in The Netherlands and inter-
nationally. He trained numerous clinicians from low-
and middle-income countries so that the benefits of
antiretroviral therapy might become available to all.
Joep was the elected President of the International
AIDS Society between 2002 and 2004, a role in which he
proved to be extremely effective. Not only did he serve
with devotion and commitment, but he travelled tire-
lessly and played a pivotal role in the organization of
several international conferences, including the HIV
Pathogenesis Conference in Paris in 2003 and the Inter-
national AIDS Conference in Bangkok in 2004. He
fought effectively for scholarship programs to be estab-
lished at such conferences in order that individuals
from developing countries might be able to participate
and present their data. He was also insistent that cap-
acity building programs become entrenched within the
International AIDS Society (IAS) in further fulfillment
of that organization’s mission. He established the IAS
Industry Liaison Forum that brings together scientific
industry representatives and experienced investigators
from low- and middle-income countries, as well as
high-income countries, to address key issues in HIV re-
search in resource-limited settings, including consider-
ations of post-trial care provision.
Joep’s partner Jacqueline worked as head nurse of the
AIDS ward in Amsterdam before joining Joep as HIV re-
search coordinator in 1990. She played a key role in clin-
ical trial conduct and in international HIV educational
efforts. She helped to guide Joep in his belief that the es-
tablishment of partnerships with academic scientists in
developing country settings represented the best way to
ensure that progress would be accomplished on an inter-
national basis. She took immense pleasure in organising
the INTEREST Workshop, a stellar scientific conference
held each year in Africa to profile the best in African
HIV science. In truth, Jacqueline also helped to round
out some of Joep’s rougher edges. Like many of those
with a burning mission to help the world’s least fortu-
nate people, he occasionally became exasperated by
opinions that he considered to be foolish. Jacqueline
made him more willing to listen to other points of view.
It is ironic that two giants in the HIV field have now
perished in airplane crashes, the other, of course, being
Jonathan Mann who died with 228 others on the Swiss
Air Flight that crashed into the Atlantic ocean off the
coast of Nova Scotia in 1998. The difference is that
Jonathan’s demise was due to an aircraft accident while
Joep’s death, together with those of 297 other victims
aboard Malaysian Airlines flight 17, is considered to be
an assassination.In summary, Joep was a profound thinker who helped
to change the world in regard to the diagnosis, treatment,
and prevention of HIV disease. He exemplified the best to
be expected in an academic physician, i.e. a sense of com-
passion, brilliance of leadership, and abhorrence of stigma
for whatever reason. Possessing a burning desire to under-
stand all aspects of the HIV epidemic, he became a
knowledgeable and reliable commentator in areas such as
epidemiology and pathogenesis that were outside his ori-
ginal clinical expertise.
Although we have lost a friend and a leader, we are
confident that his memory will live on through activ-
ities that will be established throughout the world in
his name. These may include Joep Lange memorial lec-
tureships and scholarship and mentorship programmes
dedicated to his memory that will assist low- and
middle-income scientists and clinicians to obtain train-
ing and to participate actively in future conferences in
our field.
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